Schrödinger, Inc. and the Tri-Institutional Therapeutics Discovery Institute, Inc.have renewed and extended, for an additional five years, an agreement reached in 2014 to provide access to Schrödinger’s Materials Science, Biologics, and Small?Molecule Drug Discovery Suites to researchers within TRI-I TDI’s member institutions.
April 12, 2018
· 3 min read